RxDoctor Payments Data

Rene Sanchez Borrero, MD

Neurology · Bayamon, PRNPI 1245455336

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.5% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 59.2% of the total.

$2,001in general payments, 2019–2025

Across 89 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$1K
  • Harmony Biosciences LLC$559
  • PBG Puerto Rico LLC$164
  • AbbVie$40
  • Jazz Pharmaceuticals Inc.$31
  • UCB, Inc.$24

What the payments were for

  • Food & beverage$1,81090%
  • Education$19010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amneal Pharmaceuticals LLC59$1,184
Harmony Biosciences LLC19$559
PBG Puerto Rico LLC7$164
AbbVie2$40
Jazz Pharmaceuticals Inc.1$31
UCB, Inc.1$24

How this compares

$2,001 in reported general payments places this provider in the 55th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$31,024
Medicare patients
66
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl19$285,984
RytaryCarbidopa/Levodopa500$202,450
Rivastigmine695$88,361
NuplazidPimavanserin Tartrate13$67,668
VimpatLacosamide26$30,667
Memantine Hcl ErMemantine Hcl343$26,512
KeppraLevetiracetam15$23,482
RivastigmineRivastigmine Tartrate315$15,270
NeuproRotigotine13$11,069
LamictalLamotrigine16$9,024
Memantine Hcl463$8,226
Rasagiline Mesylate83$7,686
Carbidopa-LevodopaCarbidopa/Levodopa245$6,524
Lacosamide59$3,835
Levetiracetam163$3,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$559$285,98419 claims
Amneal Pharmaceuticals LLCRytary$1,184$202,450500 claims
UCB, Inc.Vimpat, Neupro$24$41,73639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 129 neurology providers in Puerto Rico.

Other neurology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →